Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company focused on developing treatments for autoimmune diseases, with a pipeline centered on FcRn inhibitor technology. The company entered the public markets in 2019 through a business combination with Health Sciences Acquisitions Corporation, a healthcare-focused special purpose acquisition company, making it a de-SPAC operating entity in the biopharmaceutical and rare-disease sector. The Form 8-K filed on August 19, 2022 (accession 0001764013-22-000108) represents a current report submitted during Immunovant's post-merger period as a Nasdaq-listed company. For complete filing history, SPAC deal terms, and ongoing company data, sign up for full access at SpacDesk.